Clinical trials: Cancer Disease Progression
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Ewing Sarcoma, Sarcoma
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Trial name
- NCT01610570
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission.
- Trial name
- NCT00725283
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 10 sites in United States, France
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal HPV Squamous Cell Carcinoma
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer
This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance…
- Trial name
- NCT07407205
- Testing
- Concurrent Chemoradiotherapy, Dynamic Contrast-Enhanced MRI Perfusion (DCE-MRI)
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether Paclitaxel and bevacizumab showed improved PFS compared to paclitaxel alone. Recent results of the AVADO study report a similar result for the combination of docetaxel and…
- Trial name
- TABEA (NCT01200212)
- Testing
- Taxane, Avastin, Taxane, Avastin, Xeloda
- Where
- Germany
- Volunteers
- 432 people
- Sponsor
- GBG Forschungs GmbH
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+)…
- Trial name
- NCT06123494
- Testing
- SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Adult Brainstem Glioma
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
This phase 2 study is a prospective cohort study. Chemotherapy alone will be proposed to adult patients suffering from a "low grade" brainstem glioma subtype showing infiltrative, non-threatening clinico-radiological progression.
- Trial name
- TEMOTRAD01 (NCT03932981)
- Testing
- Temozolomide
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carcinoma, Hepatocellular
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
- Trial name
- NCT06530784
- Testing
- Cryoablation, PD-1 antibody and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Breast Cancer
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast…
- Trial name
- NCT05068726
- Testing
- 18F Fluoroestradiol Radiopharmaceutical with PET/CT
- Where
- 24 sites in United States
- Volunteers
- 51 people
- Sponsor
- GE Healthcare
Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC)
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both…
- Trial name
- NCT07618793
- Testing
- Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- zhang yi
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
- Trial name
- TAGVEN (NCT07007052)
- Testing
- Venetoclax, Tagraxofusp
- Where
- 34 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Nasopharyngeal Neoplasms, PD-1 Inhibitor
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined…
- Conditions
- Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
- Trial name
- NCT06811844
- Testing
- Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy
- Where
- 3 sites in China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Ovarian Cancer, Ovarian Cancer Metastatic Recurrent
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery.
- Trial name
- OC-POP-PT (NCT06839144)
- Testing
- Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)
- Where
- 2 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Lung Neoplasms, Progression
Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and…
- Trial name
- NCT06409416
- Testing
- Analysis of diagnostic biomarkers
- Volunteers
- 20 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Glioblastoma, Glioblastoma Multiforme
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
The trial is designed as a multicenter randomized controlled study. 246 patients with presumed Glioblastoma Multiforme in eloquent areas on diagnostic MRI will be selected by the neurosurgeons according the eligibility criteria…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV
- Trial name
- SAFE (NCT03861299)
- Testing
- Awake craniotomy, Craniotomy under general anesthesia
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 246 people
- Sponsor
- Jasper Gerritsen
Breast Cancer
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
This is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4/6 inhibitors and Fulvestrant in patients with…
- Trial name
- NCT07117630
- Testing
- L-Ornithine L-Aspartate, CDK4/6 inhibitor, Fulvestrant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Advanced Non-small Cell Lung Cancer
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
Phase II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) combined with Docetaxel in Advanced Non-Small Cell Lung Cancer whose disease has progressed after…
- Trial name
- NCT05215067
- Testing
- AK104, Docetaxel
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Akeso
Breast Cancer
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Breast cancer is kind of highly heterogeneous tumor. The patients with the same stage and with the same treatment regimen, their prognosis varies greatly, mainly due to the different phenotypes of breast cancer and different…
- Trial name
- NCT05659056
- Testing
- Pyrotinib, trastuzumab, paclitaxel-albumin
- Where
- China
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ovarian Cancer, Carcinosarcoma
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
This study is a phase II, multi-centre, open label study in patients with advanced ovarian cancer. The treatment being tested is Pamiparib, with daily dosing.
- Trial name
- PRECISE (NCT03933761)
- Testing
- Pamiparib
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
- Trial name
- NCT04850846
- Testing
- Metformin XR
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.